Patents by Inventor Pierre Schelling

Pierre Schelling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Sulfamidothienopyrimidines
    Publication number: 20040063943
    Abstract: The invention relates to compounds of the formula (I) in which R1, E2 and X are as defined above.
    Type: Application
    Filed: June 20, 2003
    Publication date: April 1, 2004
    Inventors: Hans-Michael Eggenweiler, Harry Schwartz, Pierre Schelling, Norbert Beier, Maria Christadler
  • Pharmaceutical formulation comprising pyrazolo[4,3-d]pyrimidines and endothelin receptor antagonists or thienopyrimidines and endothelin receptor antagonists
    Publication number: 20040063731
    Abstract: Pharmaceutical preparation comprising at least one phosphodiesterase V inhibitor have, and/or physiologically acceptable salts and/or solvates thereof and at least one endothelin receptor antagonist for the preparation of a medicament for the treatment of angina, high blood pressure, high pulmonary pressure, congestive heart failure (CHF), chronic obstructive pulmonary disease (COPD), cor pulmonale, dextrocardiac insufficiency, atherosclerosis, conditions of reduced patency of the heart vessels, peripheral vascular diseases, strokes, bronchitis, allergic asthma, chronic asthma, allergic rhinitis, glaucoma, irritable bowel syndrome, tumours, renal insufficiency, liver cirrhosis, erectile dysfunction and for the treatment of female sexual disorders.
    Type: Application
    Filed: July 31, 2003
    Publication date: April 1, 2004
    Inventors: Hans-Michael Eggenweiler, Volker Eiermann, Pierre Schelling
  • 2-Aminoalkyl-thieno[2,3-d]pyrimidines
    Publication number: 20040044011
    Abstract: The present invention relates to 2-aminomethylthieno[2,3-d]pyrimidines of the general formula (I) 1
    Type: Application
    Filed: September 16, 2003
    Publication date: March 4, 2004
    Inventors: Rochus Jonas, Pierre Schelling, Maria Christadler, Norbert Beier
  • 5-Aminoalkyl-pyrazolo[4,3-d]pyrimidines with a phosphodiesterase v-inhibiting effect
    Publication number: 20040029900
    Abstract: The present invention relates to 5-aminomethylpyrazolo[4,3-d]pyrimidines of the general formula (I) 1
    Type: Application
    Filed: June 9, 2003
    Publication date: February 12, 2004
    Inventors: Rochus Jonas, Pierre Schelling, Maria Christadler, Norbert Beier
  • Thienopyrimidines
    Publication number: 20030187260
    Abstract: Thienopyrimidines of the formula (I) and their physiologically acceptable salts, in which R1, R2 and X are as defined in claim 1, exhibit phosphodiesterase V inhibition and can be employed for the treatment of illnesses of the cardiovascular system and for the treatment and/or therapy of impotence.
    Type: Application
    Filed: March 3, 2003
    Publication date: October 2, 2003
    Inventors: Rochus Jonas, Hans-Michael Eggenweiler, Pierre Schelling, Maria Christadler, Norbert Beier
  • Condensed thienopyrimidines with phosphodiesterase-v inhibiting action
    Patent number: 6495557
    Abstract: Thienopyrimidines of the formula I and their physiologically acceptable salts, in which R1, R2 and X have the meanings given in claim 1, inhibit phosphodiesterase V and can be employed for the treatment of illnesses of the cardiovascular system and for the treatment and/or therapy of impaired potency.
    Type: Grant
    Filed: March 23, 2001
    Date of Patent: December 17, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Rochus Jonas, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Thienopyrimidines
    Patent number: 6495554
    Abstract: The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.
    Type: Grant
    Filed: May 16, 2002
    Date of Patent: December 17, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Rochus Jonas, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Thienopyrimidines
    Publication number: 20020132818
    Abstract: The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.
    Type: Application
    Filed: May 16, 2002
    Publication date: September 19, 2002
    Applicant: Merck Patent GmbH
    Inventors: Rochus Jonas, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Thienopyrimidines
    Patent number: 6420368
    Abstract: The thienopyrimidines of the formula (I) and their physiologically compatible salts display a phosphodiesterase V inhibiting activity and can be used for treating diseases of the cardiovascular system and for treatment and/or therapy of erectile dysfunction.
    Type: Grant
    Filed: May 26, 2000
    Date of Patent: July 16, 2002
    Assignee: Merck Patent Gesellschaft mit beschraenkter Haftung
    Inventors: Rochus Jonas, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Aminothiophene carboxylic acid amides and the use thereof as phosphodiesterase inhibitors
    Patent number: 6143777
    Abstract: Aminothiophenecarboxamides of the formula I ##STR1## and their physiologically acceptable salts, whereinR.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, A and n have the meanings stated in claim 1, exhibit phosphodiesterase V inhibition and can be used for the treatment of diseases of the cardiovascular system and for the therapy of disturbances of potency.
    Type: Grant
    Filed: April 14, 1999
    Date of Patent: November 7, 2000
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Rochus Jonas, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Thienopyrimidine with phosphodiesterase V inhibiting effect
    Patent number: 6130223
    Abstract: The invention relates to thienopyrimidine of the formula (I) as well as to their physiologically acceptable salts, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and n have the meaning cited in claim 1. Said compounds exhibit a phosphodiesterase V inhibition and can be used in the treatment of cardiovascular dieases and for the treatment and/or therapy potency disorder.
    Type: Grant
    Filed: June 11, 1999
    Date of Patent: October 10, 2000
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Rochus Jonas, Pierre Schelling, Maria Christadler, Franz-Werner Kluxen
  • Thienopyrimidines
    Patent number: 6110920
    Abstract: Thienopyrimidines of the formula I ##STR1## and the physiologically acceptable salts thereof in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and n have the meanings given in Claim 1inhibit phosphodiesterase V and can be employed for the treatment of diseases of the cardiovascular system and for the therapy of impaired potency.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: August 29, 2000
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Jonas Rochus, Pierre Schelling, Franz-Werner Kluxen, Maria Christadler
  • Imidazopyridines
    Patent number: 6037349
    Abstract: Imidazopyridine derivatives ad pharmacologically acceptable salts having antagonistic properties towards angiotensin II can be used for the treatment of hypertension, aldosteronism and cardiac insufficiency.
    Type: Grant
    Filed: January 4, 1999
    Date of Patent: March 14, 2000
    Assignee: Merck Patent GmbH
    Inventors: Werner Mederski, Johannes Sombroek, Pierre Schelling, Norbert Beier, Ingeborg Lues, Klaus-Otto Minck
  • Imidazopyridines
    Patent number: 5798364
    Abstract: Imidazopyridine derivatives and pharmacologically acceptable salts having antagonistic properties towards angiotensin II can be used for the treatment of hypertension, aldosteronism and cardiac insufficiency.
    Type: Grant
    Filed: October 4, 1996
    Date of Patent: August 25, 1998
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Werner Mederski, Johannes Sombroek, Pierre Schelling, Norbert Beier, Ingeborg Lues, Klaus-Otto Minck
  • Imidazopyridines as pharmaceutical agents
    Patent number: 5684015
    Abstract: Described herein are novel imidazopyridine derivatives of the formula I ##STR1## wherein R is ##STR2## and R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined in Patent Claim 1, and their salts, which exhibit antagonistic properties towards angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.
    Type: Grant
    Filed: September 14, 1995
    Date of Patent: November 4, 1997
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Werner Mederski, Matthias Osswald, Pierre Schelling, Klaus-Otto Minck, Dieter Dorsch, Norbert Beier, Ingeborg Lues
  • Imidazopyridines
    Patent number: 5532276
    Abstract: Novel imidazopyridine derivatives of the formula ##STR1## wherein R is ##STR2## and R.sup.1, R.sup.2, R.sup.3, R.sup.4, Ar.sup.1, X and Y are as defined in the specification, and their salts, exhibit antagonistic properties toward angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.
    Type: Grant
    Filed: December 5, 1994
    Date of Patent: July 2, 1996
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Werner Mederski, Dieter Dorsch, Mathias Osswald, Norbert Beier, Pierre Schelling, Klaus-Otto Minck, Ingeborg Lues
  • Imidazopyridines
    Patent number: 5476857
    Abstract: Novel imidazopyridine derivatives of formula I: ##STR1## wherein R is ##STR2## and R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and Y are as defined herein, and their salts, exhibit antagonistic properties toward angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.
    Type: Grant
    Filed: June 17, 1993
    Date of Patent: December 19, 1995
    Assignee: Merck Patent Gesellschaft mit Beschrankter Haftung
    Inventors: Werner Mederski, Dieter Dorsch, Norbert Beier, Pierre Schelling, Ingeborg Lues, Klaus-Otto Minck, Mathias Osswald
  • Imidazopyridines as angiotensin II antagonists
    Patent number: 5438063
    Abstract: Novel imidazopyridine derivatives of formula I ##STR1## wherein ##STR2## and R.sup.1, R.sup.2, R.sup.3, R.sup.4, X and Y are as defined herein, and their salts, exhibit antagonistic properties toward angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.
    Type: Grant
    Filed: June 6, 1994
    Date of Patent: August 1, 1995
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Mathias Osswald, Werner Mederski, Dieter Dorsch, Pierre Schelling, Norbert Beier, Ingeborg Lues, Klaus-Otto Minck
  • Imidazopyridines
    Patent number: 5405964
    Abstract: Novel imidazopyridine derivatives of formula I ##STR1## and X, --Y.dbd.Z--, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 as defined herein, and their salts, exhibit antagonistic properties towards angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and increased intraocular pressure, and of disorders of the central nervous system.
    Type: Grant
    Filed: October 22, 1993
    Date of Patent: April 11, 1995
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Werner Mederski, Dieter Dorsch, Andreas Bathe, Thorsten Hartig, Mathias Osswald, Norbert Beier, Pierre Schelling, Klaus-Otto Minck, Ingeborg Lues
  • Benzimidazole compounds
    Patent number: 5401738
    Abstract: Benzimidazole compounds of the formula I ##STR1## and salts thereof, exhibit antagonistic properties toward angiotensin II and can be used for the treatment of hypertension, aldosteronism, cardiac insufficiency and an increased intraocular pressure, as well as disturbances of the central nervous system.
    Type: Grant
    Filed: June 11, 1993
    Date of Patent: March 28, 1995
    Assignee: Merck Patent Gesellschaft mit beschrankter
    Inventors: Werner Mederski, Dieter Dorsch, Norbert Beier, Pierre Schelling, Ingeborg Lues, Klaus-Otto Minck, Mathias Osswald